A Phase Ib Trial of Vemurafenib Plus Copanlisib to Enhance Radioiodine Avidity in Radioiodine-Refractory Thyroid Cancers
Latest Information Update: 01 Mar 2024
At a glance
- Drugs Copanlisib (Primary) ; Vemurafenib (Primary)
- Indications Carcinoma; Thyroid cancer
- Focus Adverse reactions
- 26 Feb 2024 Status changed from active, no longer recruiting to completed.
- 09 Feb 2023 Status changed from recruiting to active, no longer recruiting.
- 03 Mar 2022 Planned End Date changed from 1 Jun 2022 to 1 Dec 2024.